{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(29)"],"submitter":["Brufsky A"],"funding":["Pfizer"],"pubmed_abstract":["<b>Aim</b>: Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer.<b>Materials & methods</b>: A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics, treatment perceptions and other clinical/nonclinical characteristics.<b>Results</b>: Efficacy and safety/tolerability were critical in oncologists' 1L decision-making. CDK4/6i use positively correlated with proportion of Medicare and postmenopausal patients (r = 0.54-0.67). Chemotherapy use demonstrated positive correlations with perimenopausal and premenopausal patients and symptom burden (r = 0.31-0.42). Aromatase inhibitor (AI) monotherapy correlated positively with anticipated treatment compliance (r = 0.42).<b>Conclusion"],"journal":["Future oncology (London, England)"],"pagination":["2165-2177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11508941"],"repository":["biostudies-literature"],"pubmed_title":["Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices."],"pmcid":["PMC11508941"],"pubmed_authors":["Kopenhafer L","Kurosky SK","Olsen P","Heck W","Arruda LS","Brufsky A","Cha-Silva AS","Maculaitis MC"],"additional_accession":[]},"is_claimable":false,"name":"Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices.","description":"<b>Aim</b>: Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer.<b>Materials & methods</b>: A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics, treatment perceptions and other clinical/nonclinical characteristics.<b>Results</b>: Efficacy and safety/tolerability were critical in oncologists' 1L decision-making. CDK4/6i use positively correlated with proportion of Medicare and postmenopausal patients (r = 0.54-0.67). Chemotherapy use demonstrated positive correlations with perimenopausal and premenopausal patients and symptom burden (r = 0.31-0.42). Aromatase inhibitor (AI) monotherapy correlated positively with anticipated treatment compliance (r = 0.42).<b>Conclusion","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-06T09:38:29.114Z","creation":"2025-04-06T09:38:29.114Z"},"accession":"S-EPMC11508941","cross_references":{"pubmed":["38861295"],"doi":["10.1080/14796694.2024.2350294"]}}